Johnson & Johnson (JNJ) Reports Q4 Adj-EPS of $0.94, Beats by 2c; Guides FY09
More News related to JNJ
- StockPreacher.com Issues Trading Outlook for Arena Pharmaceuticals Inc.
- Emerging Agents from Theravance/Astellas, Johnson & Johnson/Basilea and Forest/Astrazeneca/Takeda Will Drive Modest Growth in the MRSA Drug Market Through 2018
- Trading Outlook for BioElectronics Corporation Issued by StockPreacher.com
- LecTec Corporation and Endo Pharmaceuticals Inc. Settle Patent Dispute
- Longer Prescribed Replacement Intervals Leads to More Stretching of Frequent Replacement Contact Lenses
Johnson & Johnson (NYSE: JNJ) reports Q4 EPS of $0.94, ex-items, 2 cents better than the analyst estimate of $0.92. Revenue for the quarter was $15.18 billion, versus the consensus of $15.3 billion.
Sees FY09 adj-EPS of $4.45-$4.55, versus the consensus of $4.61.
Johnson & Johnson engages in the research and development, manufacture, and sale of various products in the health care field worldwide.
Related Categories
EarningsGuidance
Hot List
Stocks Mentioned
-0.12Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
